drug ineffective; sars-cov-2 infection; this is a spontaneous report received from a contactable reporter(s) (consumer or other non hcp) from the regulatory authority and product quality group. a 50-year-old male patient received bnt162b2 (bnt162b2), administration date 13may2021 (lot number: fe3380) as dose 1, single for covid-19 immunisation. the patient's relevant medical history and concomitant medications were not reported. the following information was reported: drug ineffective (medically significant) with onset 18feb2022, outcome "unknown", described as "drug ineffective"; covid-19 (medically significant) with onset 18feb2022, outcome "recovering", described as "sars-cov-2 infection". the patient underwent the following laboratory tests and procedures: sars-cov-2 test: positive, notes: yes - positive covid-19 test. clinical course: it was unsure if patient had symptoms associated with covid-19. patient is not enrolled in clinical trial. the report of the patient was not related to possible inflammation of the heart (myocarditis or pericarditis). no follow-up attempts are possible. no further information is expected

test name: covid-19 virus test; test result: positive ; comments: yes - positive covid-19 test

na

na